Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
AVTX Avalo Therapeutics
5.460
+0.140+2.63%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
1,007.33% 14.95M -69.21% 1.03M 147.99% 1.17M -19.42% 5.4M
Operating revenue
1,007.33% 14.95M -69.21% 1.03M 147.99% 1.17M -19.42% 5.4M
Cost of revenue
-41.85% 528K 1,787.95% 1.57M 835.06% 720K 396.67% 1.49M
Gross profit
3,162.67% 14.42M -116.32% -534K 14.39% 453K -38.94% 3.91M
Operating expense
-38.92% 10.33M -44.64% 11.29M -31.22% 21.31M 60.25% 86.04M
Selling and administrative expenses
-44.58% 3.28M -62.40% 2.78M 118.56% 11.68M 24.80% 24.66M
-Selling and marketing expense
-99.19% 6K -98.22% 14K 343.22% 1.93M 20.71% 2.83M
-General and administrative expense
-36.82% 3.28M -58.14% 2.77M 98.66% 9.76M 25.35% 21.83M
Research and development costs
-33.26% 7.04M -32.29% 8.51M -61.98% 9.58M 85.87% 59.84M
Depreciation amortization depletion
-- 0 -- 0 -91.04% 38K -11.09% 1.55M
-Depreciation and amortization
-- 0 -- 0 -91.04% 38K -11.09% 1.55M
Operating profit
124.87% 4.1M 30.95% -11.83M 31.81% -20.85M -73.67% -82.13M
Net non-operating interest income expense
8.83% -898K -382.85% -1.15M -6,976.47% -1.17M -4,992.27% -2.39M
Non-operating interest expense
-8.83% 898K -- 1.15M -- -- -- --
Total other finance cost
-- -- -- -- -- 1.17M -- 2.39M
Other net income (expense)
-20K 99.90% -20K
Special income (charges)
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
-- -- -- -- -- -20K -104.88% -20K
Income before tax
118.31% 3.2M 25.27% -12.98M 27.88% -22.04M -25.86% -84.55M
Income tax
-37.50% 5K 102.51% 5K -18.18% 9K 92.98% -196K
Net income
118.35% 3.19M 24.07% -12.99M 28.13% -22.05M -32.88% -84.38M
Net income continuous Operations
118.27% 3.19M 24.38% -12.99M 27.88% -22.05M -31.01% -84.35M
Net income discontinuous operations
-- 0 -- 0 -- 0 -103.06% -27K
Minority interest income
Net income attributable to the parent company
118.35% 3.19M 24.07% -12.99M 28.13% -22.05M -32.88% -84.38M
Preferred stock dividends
Other preferred stock dividends
74.41% -1.5M
Net income attributable to common stockholders
118.35% 3.19M 24.07% -12.99M 23.03% -22.05M -43.79% -82.88M
Basic earnings per share
116.67% 0.34 36.11% -1.38 37.50% -2.4 3.49% -9.96
Diluted earnings per share
116.67% 0.34 36.11% -1.38 37.50% -2.4 3.49% -9.96
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Listing Date: 11/13/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist